On behalf of the SFGM-TC: prophylactic donor lymphocyte infusion in patients treated with allogeneic stem-cell transplantation for high-risk myelodysplastic syndrome and acute myeloid leukemia.

Date publication

janvier 2023

Journal

Acta haematologica

Auteurs

Membres identifiés du Cancéropôle Est :
Pr RUBIO Marie Thérèse , Dr DAGUINDAU Etienne , Dr D'AVENI-PINEY Maud

Tous les auteurs :
Guisnel C, Schirmer L, Morisset S, Robin M, Labussière-Wallet H, Duléry R, Ceballos P, Forcade E, Nguyen S, Poiré X, Maertens J, Chantepie S, Chevallier P, Daguindau E, Villate A, Charbonnier A, Castilla-Llorente C, Contentin N, Huynh A, Yakoub-Agha I, Bulabois CE, Rubio MT, D'Aveni M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36603565

Résumé

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the best curative option for high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Unfortunately, it is still associated with a significant risk of relapse due to mechanisms of escape from the control of alloreactive T cells. Repetitive adjuvant donor lymphocyte infusions (DLI), termed prophylactic DLI (proDLI), as an effective strategy in preventing relapse is still debated.

Référence

Acta Haematol. 2023 01 5;: